Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 1.00 |
| ▸ | ACHE | P22303 | 4/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 4/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.84 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.84 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.72 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.69 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.69 |
| ▸ | ESR1 | P03372 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.64 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nymphaeol A SCHEMBL16105856 | 1.00 | ELANE (1.00) | ELANEACHEPTGS2ALOX5TP53 | |
| Nymphaeol A SCHEMBL30637584 | 1.00 | ELANE (1.00) | ELANEACHEPTGS2ALOX5TP53 | |
| Nymphaeol A SCHEMBL7795014 | 1.00 | ELANE (1.00) | ELANEACHEPTGS2ALOX5TP53 | |
| Nymphaeol A SCHEMBL30532526 | 1.00 | ELANE (1.00) | ELANEACHEPTGS2ALOX5TP53 | |
| Nymphaeol A SCHEMBL909992 | 1.00 | ELANE (1.00) | ELANEACHEPTGS2ALOX5TP53 | |
| SCHEMBL16105743 | 0.99 | ELANE (0.98) | ELANEACHEPTGS2ALOX5TP53 | |
| SCHEMBL3238475 | 0.99 | ELANE (0.98) | ELANEACHEPTGS2ALOX5TP53 | |
| SCHEMBL12909498 | 0.99 | ELANE (0.98) | ELANEACHEPTGS2ALOX5TP53 | |
| SCHEMBL26621041 | 0.93 | ELANE (0.86) | ELANEACHEPTGS2ALOX5TP53 | |
| SCHEMBL13043321 | 0.93 | ELANE (0.86) | ELANEACHEPTGS2ALOX5TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3946271-B1 | METHOD OF PRODUCTION OF A COMPOSITE OF YEAST-DERIVED BETA GLUCAN PARTICLE WITH INCORPORATED POORLY-WATER-SOLUBLE LOW-MOLECULAR-WEIGHT COMPOUND, PHARMACEUTICAL PREPARATION AND USE THEREOF | VS CHEMICKO TECHNOLOGICKA V PRAZE (CZ) | 2024-12-25 | — | — | EP | claimed |
| US-20220192985-A1 | METHOD OF PRODUCTION OF A COMPOSITE OF YEAST-DERIVED BETA GLUCAN PARTICLE WITH INCORPORATED POORLY-WATER-SOLUBLE LOW-MOLECULAR-WEIGHT COMPOUND, PHARMACEUTICAL PREPARATION AND USE THEREOF | VYSOKA SKOLA CHEMICKO-TECHNOLOGICKA V PRAZE (CZ) | 2022-06-23 | — | — | US | claimed |
| EP-3946271-A1 | METHOD OF PRODUCTION OF A COMPOSITE OF YEAST-DERIVED BETA GLUCAN PARTICLE WITH INCORPORATED POORLY-WATER-SOLUBLE LOW-MOLECULAR-WEIGHT COMPOUND, PHARMACEUTICAL PREPARATION AND USE THEREOF | Vysoká skola chemicko-technologická v Praze (CZ) | 2022-02-09 | — | — | EP | claimed |
| WO-2020200337-A1 | METHOD OF PRODUCTION OF A COMPOSITE OF YEAST-DERIVED BETA GLUCAN PARTICLE WITH INCORPORATED POORLY-WATER-SOLUBLE LOW-MOLECULAR-WEIGHT COMPOUND, PHARMACEUTICAL PREPARATION AND USE THEREOF | VYSOKA SKOLA CHEMICKO-TECHNOLOGICKA V PRAZE (CZ) | 2020-10-08 | — | — | WO | claimed |
| CN-101883574-B | Periodontal bacterial growth inhibitor, oral hygiene product, and food and drink | POKKA CORP | 2013-06-26 | — | — | CN | claimed |
| US-20250381166-A1 | Cannabis-Derived Flavonoids And Related Methods | CANURTA INC (CA) | 2025-12-18 | — | — | US | disclosed |
| US-12485105-B2 | Composition for suppressing obesity | DAICEL CORPORATION (JP) | 2025-12-02 | — | — | US | disclosed |
| EP-3946271-B1 | METHOD OF PRODUCTION OF A COMPOSITE OF YEAST-DERIVED BETA GLUCAN PARTICLE WITH INCORPORATED POORLY-WATER-SOLUBLE LOW-MOLECULAR-WEIGHT COMPOUND, PHARMACEUTICAL PREPARATION AND USE THEREOF | VS CHEMICKO TECHNOLOGICKA V PRAZE (CZ) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023141695-A1 | CANNABIS-DERIVED FLAVONOIDS AND RELATED METHODS | CANURTA INC. (CA) | 2023-08-03 | — | — | WO | disclosed |
| US-20230040395-A1 | COMPOSITION FOR SUPPRESSING OBESITY | DAICEL CORPORATION (JP) | 2023-02-09 | — | — | US | disclosed |
| EP-4079302-A1 | COMPOSITION FOR SUPPRESSING OBESITY | Daicel Corporation (JP) | 2022-10-26 | — | — | EP | disclosed |
| US-20220192985-A1 | METHOD OF PRODUCTION OF A COMPOSITE OF YEAST-DERIVED BETA GLUCAN PARTICLE WITH INCORPORATED POORLY-WATER-SOLUBLE LOW-MOLECULAR-WEIGHT COMPOUND, PHARMACEUTICAL PREPARATION AND USE THEREOF | VYSOKA SKOLA CHEMICKO-TECHNOLOGICKA V PRAZE (CZ) | 2022-06-23 | — | — | US | disclosed |
| EP-2186806-A1 | Flavanone compound and uses thereof | POKKA CORPORATION (JP) | 2010-05-19 | — | — | EP | disclosed |
| EP-1640371-A4 | FLAVANONE COMPOUND AND USES THEREOF | POKKA CORP (JP) | 2009-06-10 | — | — | EP | disclosed |
| US-7256214-B2 | 5,7,3',4'-Tetrahydroxy-5'-C-geranylflavanone (isonymphaeol-B), isolated from an Okinawa propolis; microbiocide, antitumor agent, food, beverage and cosmetic preservative; antioxidant food supplement | POKKA CORPORATION (JP) | 2007-08-14 | — | — | US | disclosed |
| US-20070161579-A1 | FLAVANONE COMPOUND AND USES THEREOF | POKKA CORPORATION (JP) | 2007-07-12 | — | — | US | disclosed |
| JP-2007039365-A | METHOD FOR PRODUCING EXTRACT OF MACARANGA TANARIUM | POKKA CORP | 2007-02-15 | — | — | JP | disclosed |
| US-20060292204-A1 | Flavanone compound and uses thereof | POKKA CORPORATION (JP) | 2006-12-28 | — | — | US | disclosed |
| EP-1640371-A1 | FLAVANONE COMPOUND AND USES THEREOF | POKKA CORPORATION (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-20050152996-A1 | Extracts of Mimulus aurantiacus for treating psoriasis and repelling insects | BUTLER Donald (US) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040395-A1 | COMPOSITION FOR SUPPRESSING OBESITY | FABP4, SREBF1, GPR119 | ELANE 2436/4885ACHE 4250/4885PTGS2 533/4885 |
| US-20070161579-A1 | FLAVANONE COMPOUND AND USES THEREOF | NQO1, GPX4, NDUFV2 | ELANE 501/4885ACHE 565/4885PTGS2 2072/4885 |
| US-12485105-B2 | Composition for suppressing obesity | FABP4, SREBF1, GPR119 | ELANE 2436/4885ACHE 4250/4885PTGS2 533/4885 |
| US-20060292204-A1 | Flavanone compound and uses thereof | NQO1, GPX4, NDUFV2 | ELANE 501/4885ACHE 565/4885PTGS2 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.